These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec). Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359 [TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887 [TBL] [Abstract][Full Text] [Related]
7. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model. Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879 [TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311 [TBL] [Abstract][Full Text] [Related]
11. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290 [TBL] [Abstract][Full Text] [Related]
12. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect. Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043 [TBL] [Abstract][Full Text] [Related]
13. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113 [TBL] [Abstract][Full Text] [Related]
14. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
15. SU11657 enhances radiosensitivity of human meningioma cells. Milker-Zabel S; Zabel-du Bois A; Ranai G; Trinh T; Unterberg A; Debus J; Lipson KE; Abdollahi A; Huber PE Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1213-8. PubMed ID: 18234428 [TBL] [Abstract][Full Text] [Related]
16. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347 [TBL] [Abstract][Full Text] [Related]
17. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364 [TBL] [Abstract][Full Text] [Related]
18. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Itashiki Y; Harada K; Ferdous T; Yoshida H Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527 [TBL] [Abstract][Full Text] [Related]
19. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Teicher BA; Alvarez E; Liu P; Lu K; Menon K; Dempsey J; Schultz RM Semin Oncol; 1999 Apr; 26(2 Suppl 6):55-62. PubMed ID: 10598556 [TBL] [Abstract][Full Text] [Related]
20. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Huang SM; Li J; Armstrong EA; Harari PM Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]